All articles tagged: Unspecified B-cell lymphoma, intrathoracic lymph nodes (C85.12)
HealthDay
14 June at 03.35 PM
Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell TherapySecond tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England Journal of Medicine.Mark P. Hamilton, M.D., Ph.D., from Stanford University in California, and colleagues examined the occurrence of second tumors after CAR T-cell therapy since 2016. |
Evalytics
19 March at 06.04 AM
FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLLThe FDA has granted accelerated approval for lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in certain adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Developed by Juno Therapeutics, the therapy, branded as Breyanzi, targets CD19 and is approved for patients who've undergone at least two prior lines of therapy, including specif |
|
HealthDay
21 December at 04.47 PM
American Society of Hematology, Dec. 9 to 12The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and |
|
HealthDay
12 December at 03.58 PM
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma PatientsFor patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) yields five-year progression-free survival (PFS) of 28.5 percent and overall survival of 40.3 percent, according to a study presented at the annual |
MedScape
28 November at 01.50 AM
Sleep-Disordered Breathing Common After StrokeSleep-disordered breathing remains common after stroke, affecting 60% of patients and showing no decline in prevalence from 2010 to 2023, a new meta-analysis suggested. |
Medpage Today
24 November at 08.00 PM
IDH Inhibitor Activity in Brain Cancer Persists With Longer Follow-UpHOUSTON -- Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after surgery versus placebo, according to a follow-up analysis of a pivotal clinical... |
Medical xPress
23 November at 01.50 PM
RNA editing is the next frontier in gene therapy—here's what you need to knowThe United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide. |
|
HealthDay
22 November at 04.44 PM
Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use DisorderSemaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD), according to a study published online Nov. 13 in JAMA Psychiatry.Markku Lähteenvuo, M.D., Ph.D., from the University of Eastern Finland in Kuopio, and colleagues conducted an observational study in Sweden using data from |
|
Medpage Today
17 November at 10.31 PM
Two Treatments That Don't Work for OsteoarthritisWASHINGTON -- If you're looking for nonsurgical osteoarthritis (OA) treatments with fewer side effects than ordinary pain relievers, two randomized trials presented here with negative results should at least narrow your search... |
|
MedScape
11 November at 07.56 AM
Scoring System Could Mean Better Access to Lung TransplantScoring system could improve access for hard-to-match candidates due to height and blood type. |
|
|
Medical xPress
07 November at 07.50 AM
How key results could influence health policyThe results of some congressional races may foreshadow who will have outsize health policy influence in Congress next year. |
|
Medpage Today
05 November at 07.00 PM
Mpox Cases in Congo May Be StabilizingGOMA, Congo -- Some health officials say mpox cases in Congo appear to be "stabilizing" -- a possible sign that the main epidemic for which the World Health Organization (WHO) made a global emergency declaration in August... |
|
Medical xPress
02 November at 07.40 AM
Insulin resistance caused by sympathetic nervous system over-activation, a paradigm-shifting study findsRutgers Robert Wood Johnson Medical School and collaborating institutions have found that overnutrition leads to insulin resistance and metabolic disorders through increased activity of the sympathetic nervous system (SNS). The study shows that reducing SNS activity can prevent insulin resistance induced by a high-fat diet, suggesting a new understanding of how obesity causes insulin resistance. |
|
MedScape
31 October at 06.30 AM
Report: Rethink Race-Based Adjustments in Clinical ToolsThe slow adoption of race-neutral tools may harm patient care outcomes, according to a new report from the National Academies of Sciences, Engineering, and Medicine. |
Newsletter for Healtcare
Join over 1.2M subscribers and receive one weekly email.
